Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities - PubMed (original) (raw)
. 2013 Oct;9(5 Suppl):S105-15.
doi: 10.1016/j.jalz.2012.11.010. Epub 2013 Apr 11.
Affiliations
- PMID: 23583235
- DOI: 10.1016/j.jalz.2012.11.010
Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities
Wagner Zago et al. Alzheimers Dement. 2013 Oct.
Abstract
Background: Clinical studies of β-amyloid (Aβ) immunotherapy in Alzheimer's disease (AD) patients have demonstrated reduction of central Aβ plaque by positron emission tomography (PET) imaging and the appearance of amyloid-related imaging abnormalities (ARIA). To better understand the relationship between ARIA and the pathophysiology of AD, we undertook a series of studies in PDAPP mice evaluating vascular alterations in the context of central Aβ pathology and after anti-Aβ immunotherapy.
Methods: We analyzed PDAPP mice treated with either 3 mg/kg/week of 3D6, the murine form of bapineuzumab, or isotype control antibodies for periods ranging from 1 to 36 weeks and evaluated the vascular alterations in the context of Aβ pathology and after anti-Aβ immunotherapy. The number of mice in each treatment group ranged from 26 to 39 and a total of 345 animals were analyzed.
Results: The central vasculature displayed morphological abnormalities associated with vascular Aβ deposits. Treatment with 3D6 antibody induced clearance of vascular Aβ that was spatially and temporally associated with a transient increase in microhemorrhage and in capillary Aβ deposition. Microhemorrhage resolved over a time period that was associated with a recovery of vascular morphology and a decrease in capillary Aβ accumulation.
Conclusions: These data suggest that vascular leakage events, such as microhemorrhage, may be related to the removal of vascular Aβ. With continued treatment, this initial susceptibility period is followed by restoration of vascular morphology and reduced vulnerability to further vascular leakage events. The data collectively suggested a vascular amyloid clearance model of ARIA, which accounts for the currently known risk factors for the incidence of ARIA in clinical studies.
Keywords: ARIA; Immunotherapy; Microhemorrhage; Vascular amyloid.
Copyright © 2013. Published by Elsevier Inc.
Similar articles
- Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Villarreal S, Zhao F, Hyde LA, Holder D, Forest T, Sondey M, Chen X, Sur C, Parker EM, Kennedy ME. Villarreal S, et al. J Alzheimers Dis. 2017;59(4):1393-1413. doi: 10.3233/JAD-170056. J Alzheimers Dis. 2017. PMID: 28800329 Free PMC article. - Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.
Blockx I, Einstein S, Guns PJ, Van Audekerke J, Guglielmetti C, Zago W, Roose D, Verhoye M, Van der Linden A, Bard F. Blockx I, et al. J Alzheimers Dis. 2016 Sep 6;54(2):723-35. doi: 10.3233/JAD-160023. J Alzheimers Dis. 2016. PMID: 27567811 - Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice.
Luo F, Rustay NR, Seifert T, Roesner B, Hradil V, Hillen H, Ebert U, Severin JM, Cox BF, Llano DA, Day M, Fox GB. Luo F, et al. J Pharmacol Exp Ther. 2010 Dec;335(3):580-8. doi: 10.1124/jpet.110.172932. Epub 2010 Sep 7. J Pharmacol Exp Ther. 2010. PMID: 20823195 - [Aβ immunotherapy for Alzheimer's disease].
Sakai K, Yamada M. Sakai K, et al. Brain Nerve. 2013 Apr;65(4):461-8. Brain Nerve. 2013. PMID: 23568994 Review. Japanese. - Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A. Panza F, et al. Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Immunotherapy. 2012. PMID: 22339463 Review.
Cited by
- Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
Loomis SJ, Miller R, Castrillo-Viguera C, Umans K, Cheng W, O'Gorman J, Hughes R, Budd Haeberlein S, Whelan CD. Loomis SJ, et al. Neurology. 2024 Feb 13;102(3):e207919. doi: 10.1212/WNL.0000000000207919. Epub 2023 Dec 28. Neurology. 2024. PMID: 38165296 Free PMC article. - Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease.
Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, Maldonado J, Donahue MJ, Schultz D, Coyne TM, Charidimou A, Schrag M. Solopova E, et al. Nat Commun. 2023 Dec 12;14(1):8220. doi: 10.1038/s41467-023-43933-5. Nat Commun. 2023. PMID: 38086820 Free PMC article. - Validation of 3- and 5-point severity scales to assess ARIA-E.
Bracoud L, Klein G, Lyons M, Scelsi MA, Wojtowicz J, Bullain S, Purcell D, Fiebach JB, Barakos J, Suhy J. Bracoud L, et al. Alzheimers Dement (Amst). 2023 Nov 23;15(4):e12503. doi: 10.1002/dad2.12503. eCollection 2023 Oct-Dec. Alzheimers Dement (Amst). 2023. PMID: 38026755 Free PMC article. - Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy.
Kelly L, Brown C, Michalik D, Hawkes CA, Aldea R, Agarwal N, Salib R, Alzetani A, Ethell DW, Counts SE, de Leon M, Fossati S, Koronyo-Hamaoui M, Piazza F, Rich SA, Wolters FJ, Snyder H, Ismail O, Elahi F, Proulx ST, Verma A, Wunderlich H, Haack M, Dodart JC, Mazer N, Carare RO. Kelly L, et al. Alzheimers Dement. 2024 Feb;20(2):1421-1435. doi: 10.1002/alz.13512. Epub 2023 Oct 28. Alzheimers Dement. 2024. PMID: 37897797 Free PMC article. Review. - Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know.
Alsufayan R, Hess C, Krings T. Alsufayan R, et al. AJNR Am J Neuroradiol. 2023 Dec 11;44(12):1358-1366. doi: 10.3174/ajnr.A7974. AJNR Am J Neuroradiol. 2023. PMID: 37591772 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical